LOTILIBCIN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C73H111N17O21.2ClH
Molecular Weight	1635.686
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.[H][C@@]1(NC(=O)[C@H](CO)NC(=O)C[C@@H](CCCC(C)C)OC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](CCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC4=CC=CC=C4)N(C)C(=O)CNC(=O)[C@H](CO)NC1=O)[C@@H](O)C(N)=O

InChI

InChIKey=VBXUDTFBJRKXBU-JCBBIFMDSA-N

InChI=1S/C73H111N17O21.2ClH/c1-38(2)17-14-20-43-32-56(94)80-53(37-92)69(106)88-59(61(98)62(77)99)71(108)87-52(36-91)63(100)79-35-57(95)89(7)54(30-41-18-10-9-11-19-41)70(107)86-49(29-39(3)4)66(103)81-46(23-15-27-74)64(101)82-47(25-26-58(96)97)65(102)85-51(33-55(76)93)68(105)84-50(31-42-34-78-45-22-13-12-21-44(42)45)67(104)83-48(24-16-28-75)72(109)90(8)60(40(5)6)73(110)111-43;;/h9-13,18-19,21-22,34,38-40,43,46-54,59-61,78,91-92,98H,14-17,20,23-33,35-37,74-75H2,1-8H3,(H2,76,93)(H2,77,99)(H,79,100)(H,80,94)(H,81,103)(H,82,101)(H,83,104)(H,84,105)(H,85,102)(H,86,107)(H,87,108)(H,88,106)(H,96,97);2*1H/t43-,46-,47+,48-,49+,50-,51-,52+,53+,54-,59-,60+,61-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C73H111N17O21
Molecular Weight	1562.7637
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9917006 | https://www.ncbi.nlm.nih.gov/pubmed/29019678 | https://adisinsight.springer.com/drugs/800011609

Lotilibcin (WAP-8294A2) is an antibiotic originally isolated from Lysobacter sp. It is active against methicillin-resistant gram-positive bacteria. Lotilibcin antimicrobial activity is due to lysis of the bacterial membrane, and its membrane-disrupting effect depends on the presence of menaquinone, an essential factor for the bacterial respiratory chain. It was developing for the treatment of susceptible bacterial infections

Originator

Approval Year

PubMed

Title	Date	PubMed
A new anti-MRSA antibiotic complex, WAP-8294A. I. Taxonomy, isolation and biological activities.	1998 Oct	9917006
Total Synthesis and Biological Mode of Action of WAP-8294A2: A Menaquinone-Targeting Antibiotic.	2018 Jul 6	29019678

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:34:29 GMT 2023` Edited by `admin` on `Fri Dec 15 16:34:29 GMT 2023`
Record UNII	J28HWY0T41
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LOTILIBCIN HYDROCHLORIDE

Common Name

English

LOTILIBCIN DIHYDROCHLORIDE

Common Name

English

Code System Code Type Description

FDA UNII

J28HWY0T41

Created by admin on Fri Dec 15 16:34:29 GMT 2023 , Edited by admin on Fri Dec 15 16:34:29 GMT 2023

PRIMARY

PUBCHEM

76971929

Created by admin on Fri Dec 15 16:34:29 GMT 2023 , Edited by admin on Fri Dec 15 16:34:29 GMT 2023

PRIMARY

Related Record Type Details


					XT4808181K

LOTILIBCIN

PARENT -> SALT/SOLVATE